• Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

    Source: Nasdaq GlobeNewswire / 24 Feb 2021 07:00:01   America/New_York

    LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually from March 9-10, 2021. The company will also host one-on-one meetings with attendees.

    A live audio webcast of the presentation will be available on-demand on the investor relations section of Autolus’ website at events starting March 9 at 7.00 a.m. EST. An archived replay will be available on the company’s website for a period of 90 days after the conference.

    About Autolus Therapeutics plc

    Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

    Contact:

    Lucinda Crabtree, PhD
    Vice President, Investor Relations and Corporate Communications
    +44 (0) 7587 372 619
    l.crabtree@autolus.com

    Julia Wilson
    +44 (0) 7818 430877
    j.wilson@autolus.com

    Susan A. Noonan
    S.A. Noonan Communications
    +1-212-966-3650
    susan@sanoonan.com


    Primary Logo

Share on,